N/A N=78 Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
Migraine
Primary: Change in 11-point Pain Scale Score After Two Hours (First Severe Headache) — -1.42; -1.14 score on a scale — p=0.65
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=300 An Integrated Strategy to Support Antiretroviral Therapy and Pre-exposure Prophylaxis Adherence for HIV Prevention in Pregnant and Breastfeeding Women
HIV-1-infection · Antenatal Care
Primary: Number of Participants Retained in Care With HIV Viral Suppression <40 Copies/mL (Groups 1a and 1b Only) — 35; 30 Participants
Phase 2 N=42 Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Phase 2 N=9 An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Candidemia · Invasive Candidiases · Candida Infection
Primary: Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC) — 88.9 Percentage of participants
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
N/A N=817 Evaluation of the Implementation and Effectiveness of IPP-HPV
HPV Vaccination
Primary: Count of Eligible Patients Agreeing to Receive a Dose of Vaccine — 686; 101 participants
Phase 2 N=109 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus · Autoimmune Diseases
Primary: Change in Stimulated C-peptide During a MMTT — 0.551; 0.506; 0.663; 0.425 Unitless back-transformed from log-scale — p== 0.5009
N/A N=164 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study
Biliary Stricture
Primary: Number of Participants With Stricture Resolution — 47; 54 Participants — p=.008
N/A N=278 Post-operative Patient Positioning Device for Improvement of Post-Operative Pain
Pain, Postoperative
Primary: Total Morphine Milliequivalent (MME) Use Postoperatively After Cesarean Delivery — 52; 68 Morphine milligram equivalents
Phase 3 N=199 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
N/A N=352 Investigation of the Two Level Simplify® Cervical Artificial Disc
Cervical Degenerative Disc Disorder
Primary: Composite Clinical Success (CCS) Rate of the Simplify® Disc — 153; 105 Participants — p=0.017
N/A N=249 Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses
Myopia
Primary: Least Squares Mean Distance VA (logMAR) With Study Lenses — -0.07; -0.08 logMAR
Phase 2 N=153 OTO-313 in Subjects With Unilateral Subjective Tinnitus
Subjective Tinnitus
Primary: Percentage of Tinnitus Functional Index (TFI) Responders at Weeks 4 and at Week 8 — 20; 27 Participants — p==0.385
Phase 3 N=917 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
Type 2 Diabetes
Primary: Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.44; -2.49; -0.95 Percentage of HbA1c
Phase 3 N=60 Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
Cystic Fibrosis
Primary: Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA — 14600; 12600; 16600; 13900 nanograms per milliliter (ng/mL)